The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

The past 3 decades have been characterized by an exponential growth in knowledge and
advances in the clinical treatment of atrial fibrillation (AF). It is now known that AF genesis …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

Introduction: Atrial fibrillation (AF) is increasing in prevalence and is associated with
significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are …

Background Catheter ablation of atrial fibrillation is typically performed with uninterrupted
anticoagulation with warfarin or interrupted non–vitamin K antagonist oral anticoagulant …

Background Four new oral anticoagulants compare favourably with warfarin for stroke
prevention in patients with atrial fibrillation; however, the balance between efficacy and …

Background—The comparative safety of dabigatran versus warfarin for treatment of
nonvalvular atrial fibrillation in general practice settings has not been established. Methods …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Atrial fibrillation (AF) confers a substantial risk of mortality and morbidity from stroke and
thrombo-embolism, and this common cardiac arrhythmia represents a major healthcare …

Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …